A Novel NAD+ Supporting Supplement Increased NAD+ Levels, Improved Well-Being, and Alleviated Aging Symptoms: A Double-Blind, Placebo-Controlled Study

Abstract Background A key factor in aging and many age-related diseases is the decline in nicotinamide adenine dinucleotide (NAD+) levels. Preclinical studies demonstrate promising results for NAD+ boosting in improving conditions of disease or aging. However, few human studies have shown meaningful improvements in physiological function or quality-of-life (QoL) with NAD+ boosting supplements. Objective This decentralized, double-blind, placebo-controlled study investigated the impact of Qualia NAD+®, a novel NAD+ supporting nutraceutical, on blood NAD+ levels and healthy aging, as assessed by QoL surveys. Methods Study participants were allocated to consume either Qualia NAD+ or placebo for 28 days. The primary outcomes were NAD+ levels that were measured at baseline and study end using a validated, self-administered, dried blood spot assay. Secondary outcomes included QoL measures that were assessed weekly. T-tests were used to compare NAD+ levels within and between study arms. Questionnaire data were compared using linear mixed-effects regression modeling. Results Sixty-three healthy adults aged 35 - 76 (n = 28 Qualia NAD+, n = 35 placebo) enrolled in the study and had their NAD+ levels assessed. Qualia NAD+ increased NAD+ levels by 67% compared to 4% in the placebo group (p < 0.001). Qualia NAD+ improved emotional well-being and vitality versus placebo at multiple timepoints (p < 0.05), while aging female symptoms improved in overall and somatic categories at day 28 versus placebo (p < 0.05). No improvements in aging symptoms were observed for males. Conclusion Qualia NAD+ increased NAD+ levels, enhanced QoL in all participants, and alleviated some aging symptoms in females compared to placebo. These findings support the need for longer-term clinical trials to clarify the sustained effects and underlying mechanisms of NAD+ supplementation on healthspan. Clinicaltrials.gov identifier: NCT06505967